Brian K Link

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. ncbi request reprint Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms
    B K Link
    Department of Internal Medicine, University of Iowa Cancer Center, University of Iowa College of Medicine, Iowa City, USA
    Int J Cancer 77:251-6. 1998
  2. doi request reprint Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?
    Brian K Link
    Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Drive, C32 GH, Iowa City, IA 52242, USA
    Curr Hematol Malig Rep 2:219-24. 2007
  3. pmc Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines
    Brian K Link
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    Leuk Lymphoma 52:994-1002. 2011
  4. pmc Monoclonal antibodies in lymphoma: the first decade
    Brian K Link
    Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Semin Hematol 45:71-4. 2008
  5. ncbi request reprint The mysteries of mantle cell lymphoma--do PET scans provide a clue?
    Brian K Link
    College of Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa, USA
    Leuk Lymphoma 49:1662-3. 2008
  6. doi request reprint Imaging guiding therapy development in lymphoma
    B K Link
    Holden Comprehensive Cancer Center, Division of Hematology Oncology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
    Clin Pharmacol Ther 84:443-5. 2008
  7. doi request reprint Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study
    Brian K Link
    University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    J Clin Oncol 28:3035-41. 2010
  8. ncbi request reprint Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
    Brian K Link
    Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
    J Immunother 29:558-68. 2006
  9. pmc Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
    Suresh Veeramani
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
    Blood 118:3347-9. 2011
  10. ncbi request reprint Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
    Vikram K Chand
    Department of Internal Medicine, University of Iowa, IA 52242, USA
    Leuk Lymphoma 47:657-63. 2006

Detail Information

Publications34

  1. ncbi request reprint Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms
    B K Link
    Department of Internal Medicine, University of Iowa Cancer Center, University of Iowa College of Medicine, Iowa City, USA
    Int J Cancer 77:251-6. 1998
    ..Both mechanisms may have been responsible for the toxicity observed in prior clinical studies...
  2. doi request reprint Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?
    Brian K Link
    Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Drive, C32 GH, Iowa City, IA 52242, USA
    Curr Hematol Malig Rep 2:219-24. 2007
    ..The subset of patients with early-stage FL presents special but still inconclusive considerations. Accrual to prospective randomized trials is needed to answer the question...
  3. pmc Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines
    Brian K Link
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    Leuk Lymphoma 52:994-1002. 2011
    ..Patients treated with rituximab but not anthracyclines had comparable survival to those treated with anthracycline but not rituximab...
  4. pmc Monoclonal antibodies in lymphoma: the first decade
    Brian K Link
    Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Semin Hematol 45:71-4. 2008
    ..Finally, possible future developments in the field will be proposed, including the use of monoclonal antibodies in ablative transplantation and in the treatment of leukemias...
  5. ncbi request reprint The mysteries of mantle cell lymphoma--do PET scans provide a clue?
    Brian K Link
    College of Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa, USA
    Leuk Lymphoma 49:1662-3. 2008
  6. doi request reprint Imaging guiding therapy development in lymphoma
    B K Link
    Holden Comprehensive Cancer Center, Division of Hematology Oncology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
    Clin Pharmacol Ther 84:443-5. 2008
    ..This paradigm will soon be challenged by new therapeutic strategies under development, but creative imaging approaches can still guide such development...
  7. doi request reprint Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study
    Brian K Link
    University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    J Clin Oncol 28:3035-41. 2010
    ....
  8. ncbi request reprint Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
    Brian K Link
    Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
    J Immunother 29:558-68. 2006
    ..Two subjects demonstrated late response. We conclude CpG 7909 can be safely given as a 2-hour IV infusion to patients with previously treated non-Hodgkin lymphoma at doses that have immunomodulatory effects...
  9. pmc Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
    Suresh Veeramani
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
    Blood 118:3347-9. 2011
    ..This finding may help explain the superior clinical outcome seen in the subset of high-affinity CD16 polymorphism lymphoma patients treated with single-agent rituximab...
  10. ncbi request reprint Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
    Vikram K Chand
    Department of Internal Medicine, University of Iowa, IA 52242, USA
    Leuk Lymphoma 47:657-63. 2006
    ..It may be possible to maintain dose intensity in the face of uncomplicated neutropenia during ABVD therapy...
  11. ncbi request reprint Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States)
    Shari Chen-Hardee
    Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA
    Cancer Causes Control 17:647-54. 2006
    ....
  12. ncbi request reprint Improved survival of follicular lymphoma patients in the United States
    Wade T Swenson
    Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:5019-26. 2005
    ..We undertook a study using a large population-based registry to analyze survival patterns among patients with FL...
  13. pmc A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma
    Emilian Racila
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa 52242, USA
    Clin Cancer Res 14:6697-703. 2008
    ..The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymphoma...
  14. ncbi request reprint Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
    ....
  15. pmc 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports
    Alexandra Thomas
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA
    Leuk Lymphoma 51:439-46. 2010
    ..02). Interpreting FDG-PET reports following curative-intent chemotherapy in patients is informative but imprecise, and incorporation of pre-therapy prognosis can improve predictive utility...
  16. pmc Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 117:1492-8. 2011
    ..47; P = .07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing...
  17. ncbi request reprint Antibody therapy of lymphoma
    George J Weiner
    Holden Comprehensive Cancer Center, Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA
    Adv Pharmacol 51:229-53. 2004
  18. ncbi request reprint Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy
    Shane D Scott
    Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr 5974 JPP, Iowa City, IA 52242, USA
    J Manag Care Pharm 9:15-21. 2003
    ..s lymphoma (NHL) treated with chemotherapy, but differences in days of therapy and mode (primary or secondary) of prophylaxis may affect clinical outcomes...
  19. ncbi request reprint Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma
    Elizabeth A Chrischilles
    Department of Epidemiology, College of Public Health, University of Iowa, Iowa City 52242, USA
    Cancer Control 10:396-403. 2003
    ....
  20. doi request reprint Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma
    Ahmad S Halwani
    Department of Medicine, University of Iowa College of Medicine, Holden Comprehensive Cancer Center, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Expert Rev Anticancer Ther 11:443-55. 2011
    ....
  21. ncbi request reprint Optic neuropathy due to anaplastic large cell lymphoma
    James G Howard
    Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Semin Ophthalmol 19:81-7. 2004
    ..To report a case of anaplastic large cell lymphoma (ALCL) of the central nervous system (CNS) producing an optic neuropathy...
  22. ncbi request reprint Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy
    Elizabeth A Chrischilles
    Health Effectiveness Research Center, College of Public Health, University of Iowa, Iowa City, 52242, USA
    Pharmacotherapy 25:668-75. 2005
    ..To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs...
  23. pmc Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
    Julie A Bowles
    Department of Internal Medicine, Holden Comprehensive Cancer Center at the University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Blood 108:2648-54. 2006
    ....
  24. pmc Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of iowa/mayo clinic specialized program of research excellence molecular epidemiology resource
    Brian K Link
    Brian K Link, Sergei I Syrbu, University of Iowa College of Medicine, Iowa City, IA and Matthew J Maurer, Grzegorz S Nowakowski, Stephen M Ansell, William R Macon, Susan L Slager, Carrie A Thompson, David J Inwards, Patrick B Johnston, Joseph P Colgan, Thomas E Witzig, Thomas M Habermann, and James R Cerhan, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN
    J Clin Oncol 31:3272-8. 2013
    ..This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use...
  25. doi request reprint A systematic review of validated methods for identifying lymphoma using administrative data
    Ronald A Herman
    Division of Drug Information Services, The University of Iowa College of Pharmacy, Iowa City, IA 52242 4710, USA
    Pharmacoepidemiol Drug Saf 21:203-12. 2012
    ..To systematically review published studies for algorithms that identified lymphoma as a health outcome of interest in administrative or claims data and examined the validity of the algorithm to identify lymphoma cases...
  26. pmc Population-based exploration of academic achievement outcomes in pediatric acute lymphoblastic leukemia survivors
    Lyndsay A Harshman
    Department of Pediatrics, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242 1053, USA
    J Pediatr Psychol 37:458-66. 2012
    ..Examine academic achievement among pediatric acute lymphoblastic leukemia survivors diagnosed during the years 1993-2008...
  27. doi request reprint Optimizing chemotherapeutic strategies for peripheral T-cell lymphomas
    Lori J Rosenstein
    Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    Clin Lymphoma Myeloma 8:S180-6. 2008
    ..Because of the relative rarity of this group of diseases, large-scale prospective clinical trials are difficult to implement. New treatment strategies are needed if we hope to improve patient outcomes...
  28. ncbi request reprint Monoclonal antibody therapy of B cell lymphoma
    George J Weiner
    Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
    Expert Opin Biol Ther 4:375-85. 2004
    ..Research geared towards understanding mAb mechanisms of action and the rational design of the next generation of mAb-based regimens will allow us to take full advantage of this exciting new mode of therapy...
  29. ncbi request reprint 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma
    David L Bushnell
    Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA 52246, USA
    Nucl Med Commun 25:839-43. 2004
    ..SSTR peptides can be labelled with beta emitters and, if sufficient tumour uptake relative to normal organs can be demonstrated, therapeutic applications can be considered...
  30. ncbi request reprint Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells
    Bernd Jahrsdorfer
    Holden Comprehensive Cancer Center, 5970Z JPP, The University of Iowa, Iowa City, IA 52242, USA
    J Leukoc Biol 77:378-87. 2005
    ..The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL...
  31. ncbi request reprint Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer
    David M Lubaroff
    Department of Urology and Roland and Ruby Holden Cancer Research Laboratories, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    Hum Gene Ther 17:220-9. 2006
  32. ncbi request reprint Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
    John P Leonard
    Center for Lymphoma and Myeloma and Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Oncol 29:81-6. 2002
    ..Further efforts will explore optimal clinical settings for their use, as well as define treatment regimens either as single agents or in combination with chemotherapy or other biologics...
  33. ncbi request reprint Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
    John P Leonard
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:6168-74. 2007
    ..This Phase I trial was designed to investigate the safety, tolerability, and preliminary antitumor activity of PF-3512676 in combination with rituximab...
  34. doi request reprint First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Blood 111:5486-95. 2008
    ..9 months at a median/maximum follow-up of 9.2/38.6 months. Ofatumumab is currently being evaluated in patients with rituximab-refractory FL. This trial was registered at www.clinicaltrials.gov as #NCT00092274...